WillemVanheeckerenMDPhD

PubMed

• 12 citations
  Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma.
  Rebecca Ye, Sirisha Kundrapu, Stanton L. Gerson, James J. Driscoll, Rose Beck
  Clinical Lymphoma, Myeloma & Leukemia. 2019-05-01

Journal Articles

• Prospective Study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies  
  Kindwall-Keller TL, Hegerfeldt Y, Meyerson HJ, Margevicius S, Fu P, van Heeckeren W, Lazarus HM, Cooper BW, Gerson SL, Barr P, Tse WW, Curtis C, Fanning LR, Creger RJ,..., Bone Marrow Transplant, 10/17/2011
• Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia  
  van Heeckeren WJ, Fu P, Barr PM, Arfons LM, Kirschbaum MH, Lazarus HM, Cooper BW, J Geriatric Oncology, 1/1/2011
• Time-Dependent Effect of Non-Hodgkin’s Lymphoma Grade on Disease Free Survival of Relapsed/Refractory Patients Treated with High-Dose Chemotherapy Plus Autotransplanta...  
  Fu P, van Heeckeren WJ, Wadhwa PD, Bajor DJ, Creger RJ, Xu Z, Cooper BW, Laughlin MJ, Lazarus HM, Gerson SL, Koc ON, Contemporary Clinical Trials, 1/1/2008
• Influence Of HLA Disparity and Graft Lymphocytes on Allogeneic Engraftment and Survival after Umbilical Cord Blood Transplant in Adults  
  van Heeckeren WJ, Fanning L, Meyerson H, Fu P, Jaroscak J, Finney M, Fox R, Lazarus H, Cooper B, Gerson S, Tse W, and Laughlin M, British Journal of Haematology, 1/1/2007
• Hypertension, Proteinuria and Antagonism of VEGF Signaling: Clinical Toxicity, Therapeutic Target or Novel Biomarker?  
  van Heeckeren WJ, Cooney MM, Ortiz J, Remick SC, Journal of Clinical Oncology, 1/1/2007
• Complications from Vascular Disrupting Agents and Angiogenesis Inhibitors: Aberrant Control of Hemostasis and Thrombosis  
  van Heeckeren WJ, Narayan A, Sanborn SL, Cooney MM, McCrae K, Schmaier A, Remick SC, Current Opinions in Hematology, 1/1/2007
• Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMA...  
  van Heeckeren WJ, Vollweiler J, Fu P, Cooper B, Meyerson H, Lazarus H, Simic A, Laughlin M, Gerson S, Koc O, British Journal of Haematology, 1/1/2006
• The promise of new vascular-disrupting agents balanced with cardiac toxicity: Is it time for oncologists to get to know their cardiologists?  
  van Heeckeren WJ, Cooney MM, Bhakta S, Ortiz J, Dowlati A, McCrae K, Duerk J, Remick SC, Journal of Clinical Oncology, 1/1/2006
• Drug Insight: vascular disrupting agents and angiogenesis – novel approaches for drug delivery  
  Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC, Nature Clinical Practice Oncology, 1/1/2006
• Exonic splicing enhancers in fission yeast: functional conservation demonstrates an early evolutionary origin  
  Webb CJ, Romfo CM, van Heeckeren WJ, Wise J, Genes & Dev, 1/1/2005
• Evidence for splice site pairing via intron definition in Schizosaccharomyces pombe  
  Romfo CM, Alvarez CJ, van Heeckeren WJ, Webb CJ, Wise J, Molecular and Cellular Biology, 1/1/2000
• The mating-type proteins of fission yeast induce meiosis by directly activating mei3 transcription  
  van Heeckeren WJ, Dorris DR, Struhl K, Molecular and Cellular Biology, 1/1/1998
• Role of the conserved leucines in the leucine zipper dimerization motif of yeast GCN4  
  van Heeckeren W, Sellers J, Struhl K, Nucleic Acids Research, 1/1/1992
• Join now to see all